Display options
Cite
Tucci MC, Dvorkin-Gheva A, Johnson E, et al. Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior. Eur J Neurosci. 2014;40(6):2971-9doi: 10.1111/ejn.12652.
Tucci, M. C., Dvorkin-Gheva, A., Johnson, E., Cheon, P., Taji, L., Agarwal, A., Foster, J., & Szechtman, H. (2014). Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior. The European journal of neuroscience, 40(6), 2971-9. https://doi.org/10.1111/ejn.12652
Tucci, Mark C, et al. "Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior." The European journal of neuroscience vol. 40,6 (2014): 2971-9. doi: https://doi.org/10.1111/ejn.12652
Tucci MC, Dvorkin-Gheva A, Johnson E, Cheon P, Taji L, Agarwal A, Foster J, Szechtman H. Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior. Eur J Neurosci. 2014 Sep;40(6):2971-9. doi: 10.1111/ejn.12652. Epub 2014 Jun 16. PMID: 24935528; PMCID: PMC4215607.
Copy Download .nbib Format: NLM
Share it on

Eur J Neurosci. 2014 Sep;40(6):2971-9. doi: 10.1111/ejn.12652. Epub 2014 Jun 16.

Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior.

The European journal of neuroscience

Mark C Tucci, Anna Dvorkin-Gheva, Eric Johnson, Paul Cheon, Leena Taji, Arnav Agarwal, Jane Foster, Henry Szechtman

Affiliations

  1. Department of Psychiatry and Behavioural Neurosciences, Health Science Centre, McMaster University, Room 4N82, 1280 Main Street West, Hamilton, ON, Canada, L8S 4K1.

PMID: 24935528 PMCID: PMC4215607 DOI: 10.1111/ejn.12652

Abstract

A previous analysis of the quinpirole sensitisation rat model of obsessive-compulsive disorder revealed that the behavioral phenotype of compulsive checking consists of three constitutive components - vigor of checking performance, focus on the task of checking, and satiety following a bout of checking. As confirmation of this analysis, the aim of the present study was to reconstitute, without quinpirole treatment, each of the putative components, with the expectation that these would self-assemble into compulsive checking. To reconstitute vigor and satiety, the employed treatment was a bilateral lesion of the nucleus accumbens core (NAc), as this treatment was shown previously to exaggerate these components. To reconstitute focus, the employed treatment was a low dose of the serotonin-1A receptor agonist 8-hydroxy-2-(di-n-propylamino) tetralin hydrochloride (DPAT) (0.0625 mg/kg), as high doses of this drug induce compulsive behavior and exacerbate focus. Results showed that injection of DPAT to NAc lesion rats did yield compulsive checking. Neither the drug alone nor the NAc lesion by itself produced compulsive checking. The demonstrated synthesis of compulsive checking by the combined treatment of low-dose DPAT and NAc lesion strengthened the previous fractionation of the model obsessive-compulsive disorder phenotype into three constitutive components, and suggested a role for serotonin-1A receptors outside the NAc in enhanced focus on the task of checking.

© 2014 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Keywords: 8-hydroxy-2-(di-n-propylamino) tetralin hydrochloride; analysis and synthesis; animal model; compulsive checking behavior; nucleus accumbens core lesion

References

  1. Neurochem Res. 1997 Aug;22(8):1065-70 - PubMed
  2. Behav Neurosci. 1998 Dec;112(6):1475-85 - PubMed
  3. Brain Res. 1999 Feb 27;820(1-2):55-62 - PubMed
  4. Psychol Rev. 2004 Jan;111(1):111-27 - PubMed
  5. Behav Brain Res. 2003 Mar 18;140(1-2):165-73 - PubMed
  6. Int Clin Psychopharmacol. 1993 Nov;8 Suppl 2:79-82 - PubMed
  7. CNS Spectr. 2003 Aug;8(8 Suppl 1):7-16 - PubMed
  8. Pharmacol Biochem Behav. 1991 Jan;38(1):63-7 - PubMed
  9. Biol Psychiatry. 1989 Jun;26(2):189-98 - PubMed
  10. Neuroreport. 1999 Feb 25;10(3):493-5 - PubMed
  11. Neuropsychopharmacology. 2006 Apr;31(4):757-67 - PubMed
  12. World J Biol Psychiatry. 2000 Apr;1(2):92-100 - PubMed
  13. Pol J Pharmacol. 1999 Jan-Feb;51(1):55-61 - PubMed
  14. J Comp Neurol. 2001 Apr 30;433(2):157-82 - PubMed
  15. Neurosci Biobehav Rev. 2001 Jul;25(5):409-26 - PubMed
  16. Br J Psychiatry Suppl. 1998;(35):26-37 - PubMed
  17. Behav Pharmacol. 2013 Feb;24(1):65-73 - PubMed
  18. Eur J Pharmacol. 1990 Jun 12;188(6):301-12 - PubMed
  19. Psychopharmacology (Berl). 2006 Jul;186(4):534-43 - PubMed
  20. Neuron. 2000 Nov;28(2):343-7 - PubMed
  21. Pharmacol Biochem Behav. 1991 Oct;40(2):311-5 - PubMed
  22. Psychopharmacology (Berl). 2013 May;227(2):277-85 - PubMed
  23. J Neuropsychiatry Clin Neurosci. 2008 Fall;20(4):390-408 - PubMed
  24. Rev Neurosci. 2010;21(2):119-39 - PubMed
  25. Psychopharmacology (Berl). 2014 Sep;231(18):3707-18 - PubMed
  26. Brain Res. 1989 Jun 26;490(2):255-67 - PubMed
  27. Physiol Behav. 2002 Aug;76(4-5):449-56 - PubMed
  28. Neurosci Biobehav Rev. 2011 May;35(6):1419-49 - PubMed
  29. J Clin Psychiatry. 1990 Aug;51 Suppl:36-43; discussion 55-8 - PubMed
  30. Jpn J Pharmacol. 1995 May;68(1):65-70 - PubMed
  31. Prog Neurobiol. 2004 Feb;72(3):195-221 - PubMed
  32. J Neurosci Methods. 2004 Feb 15;133(1-2):161-72 - PubMed
  33. PLoS One. 2011;6(9):e25217 - PubMed
  34. Mol Psychiatry. 2006 Jul;11(7):622-32 - PubMed
  35. Behav Brain Res. 1989 Sep 1;34(3):199-211 - PubMed
  36. Behav Neurosci. 2001 Dec;115(6):1301-17 - PubMed
  37. Neuropsychiatr Dis Treat. 2005 Sep;1(3):231-43 - PubMed
  38. Neuropharmacology. 1999 Aug;38(8):1083-152 - PubMed
  39. Synapse. 2006 Dec 15;60(8):599-608 - PubMed
  40. Physiol Behav. 2001 Aug;73(5):731-44 - PubMed
  41. Neurobiol Dis. 2012 Sep;47(3):393-406 - PubMed
  42. Pharmacol Biochem Behav. 2002 Apr;71(4):533-54 - PubMed
  43. CNS Spectr. 2005 Mar;10(3):191-202 - PubMed
  44. Anxiety. 1994-1995;1(5):208-15 - PubMed
  45. Lancet. 2002 Aug 3;360(9330):397-405 - PubMed
  46. J Clin Psychol. 2004 Nov;60(11):1155-68 - PubMed
  47. Anim Behav. 1999 Apr;57(4):807-817 - PubMed
  48. Psychopharmacology (Berl). 1994 Jun;115(1-2):95-104 - PubMed
  49. J Neurosci Methods. 2000 Mar 15;96(2):119-31 - PubMed
  50. Psychopharmacology (Berl). 2003 May;167(3):304-14 - PubMed
  51. Pharmacol Rev. 2007 Dec;59(4):360-417 - PubMed
  52. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53 - PubMed
  53. Front Neurosci. 2010 Jun 17;4:35 - PubMed
  54. Behav Brain Res. 1993 Feb 26;53(1-2):21-33 - PubMed
  55. J Anxiety Disord. 2008;22(2):143-61 - PubMed
  56. Behav Res Methods Instrum Comput. 2001 Aug;33(3):398-414 - PubMed
  57. PLoS One. 2012;7(1):e30586 - PubMed
  58. Psychopharmacology (Berl). 2011 Feb;213(2-3):213-42 - PubMed
  59. Behav Brain Res. 2012 Jun 1;231(2):234-49 - PubMed
  60. J Pharmacol Exp Ther. 2006 Feb;316(2):830-4 - PubMed
  61. Arch Int Pharmacodyn Ther. 1990 Jul-Aug;306:106-13 - PubMed
  62. Pharmacol Rep. 2009 Sep-Oct;61(5):761-77 - PubMed
  63. J Clin Psychiatry. 1992 Apr;53 Suppl:4-10 - PubMed
  64. Eur J Neurosci. 2010 Nov;32(9):1552-63 - PubMed
  65. J Clin Psychol. 2004 Nov;60(11):1195-202 - PubMed
  66. J Theor Biol. 1998 Sep 21;194(2):235-50 - PubMed
  67. Behav Brain Res. 2006 May 15;169(2):303-11 - PubMed

Substances

MeSH terms

Publication Types